TELCAGEPANT POTASSIUM
Total Payments
$64,103
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $18,315 | 1 | 0 |
| 2018 | $45,788 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $64,103 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| The Utility of Telemedicine in the Management of Patients with Migraine A Pilot Study | Merck Sharp & Dohme Corporation | $64,103 | 0 |
Top Doctors Receiving Payments for TELCAGEPANT POTASSIUM
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Dallas, TX | $64,103 | 2 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $64,103
Product Information
- Type Drug
- Total Payments $64,103
- Total Doctors 0
- Transactions 2
About TELCAGEPANT POTASSIUM
TELCAGEPANT POTASSIUM is a drug associated with $64,103 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2019. In 2019, $18,315 was paid across 1 transactions to 0 doctors.
The most common payment nature for TELCAGEPANT POTASSIUM is "Unspecified" ($64,103, 100.0% of total).
TELCAGEPANT POTASSIUM is associated with 1 research study, including "The Utility of Telemedicine in the Management of Patients with Migraine A Pilot Study" ($64,103).